NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-DK-21-503 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to continue to follow the Epidemiology of Diabetes Interventions and Complications (EDIC) cohort through a collaborative cooperative agreement. EDIC is an observational study that was launched at the completion of the Diabetes Control and Complications Trial (DCCT) trial. The DCCT showed that intensive therapy significantly reduced the risk of diabetes complications compared to conventional therapy. At DCCT completion, all cohort members were taught intensive diabetes therapy. In 1994, EDIC was launched to: (1) evaluate the long-term effects of DCCT intensive therapy, (2) describe the long-term effects of glycemia and other risk factors on diabetes complications, and (3) characterize type1 diabetes complicationsby supporting collaborative research to utilize the EDIC cohort as well as its data set and biologic/genetic samples. To date, EDIC has: (1) demonstrated a continued benefit of intensive therapy on the development and progression of diabetes complications, and (2) characterized the development and progression of diabetes complications. The primary purpose of this FOA is to support the EDIC Research Center to continue follow-up of the EDIC cohort to study the development of complications and the longer term course of type 1 diabetes in a well characterized type 1 diabetes population, including but not limited to severe microvascular disease (blindness, kidney failure, amputation),cardiovascular disease, liver disease, sleep disorders and mortality. The EDIC Research Center will manage and support EDIC Clinical Centers, which are responsible for the conduct of all EDIC core activities as described in the protocol and Manual of Operations and as required by the local and central Institutional Review Boards.
Funding Opportunity PAR-21-316 from the NIH Guide for Grants and Contracts. Reissue of PAR-17-264. The purpose of this funding announcement is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities for mental health services research.
Notice of Special Interest (NOSI): Advancing the development of tumor site-activated small molecules
Notice NOT-CA-21-101 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-173 from the NIH Guide for Grants and Contracts
Notice NOT-HS-21-019 from the NIH Guide for Grants and Contracts
Notice NOT-MH-21-320 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-107 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DE-22-005 from the NIH Guide for Grants and Contracts. The goal of this initiative is to encourage research focused on deciphering the cellular and molecular mechanisms underpinning temporomandibular joint disorders (TMJD) pain and tissue dysfunction using single-cell omics approaches. Delineation of cellular and molecular mechanisms that mediate TMJD resolution and homeostasis are also desired. Identification of cell populations and their effector pathways, in TMJD target tissue (e.g. synovial fluid, muscle, skin), as 1) molecular disease classifiers allowing for patient stratification, 2) diagnostic, prognostic, and/or predictive biomarkers, and/or 3) novel therapeutic targets are desired outcomes of this initiative.
Funding Opportunity RFA-DA-22-022 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research to understand and respond to new challenges in the treatment of drug addiction and overdose, introduced by the now widespread presence of fentanyl and its analogs (fentanils) in illicit drug supplies. The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Applications may focus on the treatment of opioid and polydrug use disorders where fentanils are a major contributor to the problem. The research may include preclinical, clinical, epidemiological or post-mortem studies, but should have high impact and quickly yield the necessary information to understand and effectively respond to the impacts of fentanils in illicit drug supplies. Studies might also aim to develop new or repurposed medications or therapeutic devices or aim to revise therapeutic standards of care. Research dependent on development and implementation of toxicological assessment techniques required to identify and quantitate fentanils and their metabolites, and other opioids or abused substances in clinical and post mortem toxicological samples may also be appropriate if the aims are to understand the public health consequences and treatment of disorders associated with the knowing or unknowing consumption of fentanils. Research to develop new therapeutic medications, indications or devices should be designed to significantly advance the program towards FDA approval for the treatment of fentanil-related Substance Use Disorders or overdose.
Notice NOT-DA-21-064 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-ES-21-008 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Phase I (R43), Phase II (R44), and Fast-track (R44) Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) in collaboration with environmental science researchers to develop novel tools, activities, or materials to build environmental health literacy for a variety of groups, including community members, health care and public health professionals, educators, and students of all ages.
Funding Opportunity RFA-ES-21-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Phase I (R41), Phase II (R42), and Fast-track (R42) Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) in collaboration with environmental science researchers to develop novel tools, activities, or materials to build environmental health literacy for a variety of groups, including community members, health care and public health professionals, educators, and students of all ages.
Funding Opportunity RFA-DK-21-017 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites cooperative agreement applications that will contribute to a higher resolution understanding of the organization of the human pancreatic tissue environment by describing the composition and function of important components of the pancreatic islet and peri-islet tissue architecture, the cell-cell relationships and means of communications used by cell types and cell subtypes within the pancreatic tissue ecosystem, and the contribution of adjacent tissues to islet cell function and dysfunction. Successful projects will integrate the Human Pancreas Analysis Consortium (HPAC) that is part of the Human Islet Research Network or HIRN (https://hirnetwork.org/). HIRN's overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This FOA will only support studies with a primary focus on increasing our understanding of human tissue structure and function, and human disease biology, as opposed to exploring the biology specific to any animal models.
Notice NOT-MH-21-321 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-21-058 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support research that combines epidemiologic methods, digital technology, and data science approaches to better understand HIV prevention, transmission, and early care-cascade points for women living in the US. Applications must: 1) determine the best ways to identify, enroll, and retain cohorts of women living in the United States (US) who are behaviorally vulnerable to HIV; and 2) knowledgebase comprised of cohort data from women augmented with other data sources including big data sources. Findings should not only lead to a better understanding of how women remain vulnerable to HIV but also inform future pilot interventions aimed at decreasing the incidence of HIV and other sexually transmitted infections (STIs) among cisgender, transgender, and gender non-conforming women.
Funding Opportunity PAR-21-307 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with Alzheimers disease (AD) and Alzheimers disease-related dementias (ADRD) and of those providing their care.
Funding Opportunity PAR-21-308 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement(FOA) will support pragmatic trials within Stage IV of the NIH Stage Model to improve dementia care across multiple dementia care settings that will: (1) be designed to address practical comparative questions faced by Alzheimers disease (AD) and AD-related dementia (ADRD) patients, clinicians, and caregivers (both paid and unpaid); (2) include broad and diverse populations; and (3) be conducted in real-world settings with adequate sample size. These trials are intended to produce results that can be directly adopted by healthcare providers, patients, or caregivers for rapid dissemination and implementation. Successful applications will: (1) improve quality of care of persons with dementia; (2) improve quality of life for persons with dementia and their informal caregivers; (3) deliver more patient-focused, cost-effective care across multiple settings; and/or (4) reduce disparities in dementia care.
Funding Opportunity PAR-21-305 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.
Notice NOT-DK-21-025 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-024 from the NIH Guide for Grants and Contracts. This FOA invites investigation of biological and clinical measures of TBI-related progressive neurodegeneration and neurocognitive decline associated with increased risk for dementia and /or traumatic encephalopathy syndrome (TES) (clinicopathologic diagnostic counterpart to the neuropathological diagnosis of Chronic Traumatic Encephalopathy (CTE)). Investigations should be based on existing, well-characterized populations of patients with a history of TBI that are enriched for increased risk of cognitive impairment or dementia and can continue to be followed longitudinally; additional subjects may be recruited as appropriate. The overall goal is to advance knowledge of the underlying pathophysiology and clinical characterization of the chronic effects of TBI that distinguish static-chronic TBI cognitive impairment from those that lead to progressive neurodegeneration associated with TES and dementia. A critical feature of this FOA includes the broad sharing of clinical, neuroimaging, physiological, and biospecimen data and to create a data and associated biofluid resource for the broader community to further advance research in this area.